

# Philippe R Lagac-Wiens

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5184575/philippe-r-lagace-wiens-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

3,179

citations

27

h-index

56

g-index

102

ext. papers

3,756

ext. citations

4.6

avg, IF

5.14

L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 66 | Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.. <i>Drugs</i> , <b>2022</b> , 1   | 12.1 | 3         |
| 65 | Evaluation of the Hologic Aptima Combo 2 Assay for Detection of Neisseria gonorrhoeae from Joint Fluid Specimens.. <i>Journal of Clinical Microbiology</i> , <b>2022</b> , e0253021   | 9.7  | 0         |
| 64 | Serologic testing for Bartonella in Manitoba, Canada, 2010-2020: a retrospective case series. <i>CMAJ Open</i> , <b>2022</b> , 10, E476-E482  | 2.5  | 0         |
| 63 | Campylobacter concisus gastritis masquerading as Helicobacter pylori on gastric biopsy. <i>Helicobacter</i> , <b>2021</b> , e12864  | 4.9  |           |
| 62 | Real-life experience with ceftobiprole in Canada: Results from the CLEAR (Canadian Leadership on Antimicrobial Real-life usage) registry. <i>Journal of Global Antimicrobial Resistance</i> , <b>2021</b> , 24, 335-339   | 3.4  | 6         |
| 61 | Seasonality of coronaviruses and other respiratory viruses in Canada: Implications for COVID-19. <i>Canada Communicable Disease Report</i> , <b>2021</b> , 47, 132-138  | 3.1  | 3         |
| 60 | In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. <i>Jammi</i> , <b>2021</b> , 6, 149-162   | 1.4  |           |
| 59 | Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , <b>2021</b> , 81, 233-256   | 12.1 | 10        |
| 58 | Bacteremia and Nodular Soft Tissue Infection in a Person Who Uses Tap Water to Inject Drugs. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa580   | 1    | 0         |
| 57 | In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2021</b> , 101, 115418 | 2.9  | 2         |
| 56 | Endocarditis due to , the etiological agent of trench fever. <i>Cmaj</i> , <b>2020</b> , 192, E1723-E1726   | 3.5  | 2         |
| 55 | In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 97, 115012  | 2.9  | 23        |
| 54 | Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007-2014. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2020</b> , 73, 266-271   | 0.5  |           |
| 53 | Prevalence, predictors, and consequences of inappropriate empiric antimicrobial therapy for complicated urinary tract and intra-abdominal infections in Winnipeg hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 96, 114891  | 2.9  | 2         |
| 52 | Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , <b>2019</b> , 155, 69-78   | 5.3  | 36        |
| 51 | Marked elevation of serum ferritin associated with Anaplasma phagocytophilum infection. <i>Jammi</i> , <b>2019</b> , 4, 37-41   | 1.4  |           |
| 50 | In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 62-68               | 14.3 | 12        |

|    |  |      |     |
|----|--|------|-----|
| 49 | Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , <b>2019</b> , 79, 271-289  | 12.1 | 160 |
| 48 | 708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011-2018. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S319-S319                            | 1    | 78  |
| 47 | 128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, S93-S93                      | 1    | 78  |
| 46 | Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 645-653  | 5.1  | 14  |
| 45 | In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible <i>Pseudomonas aeruginosa</i> clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 703-708                                | 5.1  | 16  |
| 44 | Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada. <i>Mycoses</i> , <b>2018</b> , 61, 743-753  | 5.2  | 26  |
| 43 | Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. <i>Drugs</i> , <b>2018</b> , 78, 65-98   | 12.1 | 202 |
| 42 | 2383. In Vitro Activity of Ceftolozane/Tazobactam in Comparison With Ceftazidime/Avibactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007-2017. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S710-S710 | 1    | 78  |
| 41 | Characterization of isolates of <i>Eisenbergiella tayi</i> , a strictly anaerobic Gram-stain variable bacillus recovered from human clinical materials in Canada. <i>Anaerobe</i> , <b>2017</b> , 44, 128-132  | 2.8  | 9   |
| 40 | Impact of Antivirals in the Prevention of Serious Outcomes Associated with Influenza in Hospitalized Canadian Adults: A Pooled Analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S18-S18                        | 1    | 78  |
| 39 | Clonal Clusters and Virulence Factors of Group C and G <i>Streptococcus</i> Causing Severe Infections, Manitoba, Canada, 2012-2014. <i>Emerging Infectious Diseases</i> , <b>2017</b> , 23, 1079-1088  | 10.2 | 11  |
| 38 | Emerging group C and group G streptococcal endocarditis: A Canadian perspective. <i>International Journal of Infectious Diseases</i> , <b>2017</b> , 65, 128-132   | 10.5 | 11  |
| 37 | Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. <i>Peritoneal Dialysis International</i> , <b>2017</b> , 37, 170-176   | 2.8  | 24  |
| 36 | Quinolones <b>2017</b> , 1239-1248.e2  |      |     |
| 35 | Antimicrobial susceptibility of 2906 <i>Pseudomonas aeruginosa</i> clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2017</b> , 87, 60-63                          | 2.9  | 13  |
| 34 | In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 <i>Stenotrophomonas maltophilia</i> Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011-2016). <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S367-S368   | 1    | 78  |
| 33 | In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008-2016. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S372-S372  | 1    | 78  |
| 32 | Quintessential Culture-Negative Endocarditis. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 395.e9-e10   | 3.8  | 5   |

|    |  |      |     |
|----|--|------|-----|
| 31 | Multifaceted antibiotic treatment analysis of methicillin-sensitive <i>Staphylococcus aureus</i> bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , <b>2016</b> , 48, 674-679  | 14.3 | 5   |
| 30 | Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , <b>2016</b> , 76, 567-88   | 12.1 | 144 |
| 29 | Frequency of MCR-1-mediated colistin resistance among <i>Escherichia coli</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). <i>CMAJ Open</i> , <b>2016</b> , 4, E641-E645  | 2.5  | 20  |
| 28 | <i>Pasteurella</i> species peritoneal dialysis-associated peritonitis: Household pets as a risk factor. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2015</b> , 26, 52-5   | 2.6  | 14  |
| 27 | Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. <i>Drugs</i> , <b>2015</b> , 75, 253-70   | 12.1 | 107 |
| 26 | Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/MS)-based identification of pathogens from positive blood culture bottles. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1237, 47-55   | 1.4  | 12  |
| 25 | 254In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. <i>Open Forum Infectious Diseases</i> , <b>2014</b> , 1, S109-S109  | 1    | 78  |
| 24 | Hemorrhagic pustules in an Aboriginal man. <i>Cmaj</i> , <b>2014</b> , 186, 607-10   | 3.5  |     |
| 23 | Changing trends in Hemolytic streptococcal bacteremia in Manitoba, Canada: 2007-2012. <i>International Journal of Infectious Diseases</i> , <b>2014</b> , 28, 211-3  | 10.5 | 12  |
| 22 | In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2554-63   | 5.9  | 90  |
| 21 | Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. <i>Core Evidence</i> , <b>2014</b> , 9, 13-25  | 4.9  | 114 |
| 20 | Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. <i>Drugs</i> , <b>2014</b> , 74, 31-51  | 12.1 | 230 |
| 19 | Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. <i>Drugs</i> , <b>2013</b> , 73, 159-77  | 12.1 | 296 |
| 18 | A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2013</b> , 24, 32-4   | 2.6  | 13  |
| 17 | Adverse reactions to β-lactam antimicrobials. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 381-99  | 4.1  | 69  |
| 16 | Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround time. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 3324-8 | 9.7  | 149 |
| 15 | Antimicrobial susceptibility of <i>Pseudomonas aeruginosa</i> isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2012</b> , 73, 361-4  | 2.9  | 5   |
| 14 | Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing <i>Escherichia coli</i> : results of the CANWARD 2007-2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2011</b> , 69, 326-34  | 2.9  | 51  |

|    |  |      |     |
|----|--|------|-----|
| 13 | Activity of NXL104 in combination with beta-lactams against genetically characterized <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 2434-7 | 5.9  | 76  |
| 12 | Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3169-75  | 5.9  | 78  |
| 11 | Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 4684-93  | 5.9  | 114 |
| 10 | Influenza epidemiology--past, present, and future. <i>Critical Care Medicine</i> , <b>2010</b> , 38, e1-9  | 1.4  | 47  |
| 9  | Prevalence and Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Isolated in Canadian Hospitals: Results from CANWARD 2007. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2009</b> , 20, 43A-48A  | 2.6  | 2   |
| 8  | Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2009</b> , 20, 9A-19A  | 2.6  | 11  |
| 7  | Antimicrobial Susceptibility of 6685 Organisms Isolated from Canadian Hospitals: CANWARD 2007. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2009</b> , 20, 20A-30A   | 2.6  | 1   |
| 6  | Cardiac Aspergillosis <b>2009</b> , 889-903  |      |     |
| 5  | Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing <i>Escherichia coli</i> from Canadian intensive care units: the 1st report of QepA in North America. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 63, 319-26  | 2.9  | 27  |
| 4  | Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant <i>Staphylococcus aureus</i> . <i>Drugs</i> , <b>2009</b> , 69, 809-31  | 12.1 | 95  |
| 3  | Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2008</b> , 62, 67-80   | 2.9  | 43  |
| 2  | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 1430-7  | 5.9  | 169 |
| 1  | Mechanical valve endocarditis caused by <i>Gemella morbillorum</i> . <i>Journal of Medical Microbiology</i> , <b>2007</b> , 56, 1689-1691  | 3.2  | 16  |